New injection aims to flush out toxic cadmium
NCT ID NCT07057414
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests an injectable drug called GMDTC in 11 adults with high cadmium levels. The goal is to see if it safely helps the body get rid of cadmium through urine. Participants will receive either the drug or a placebo, and researchers will measure changes in cadmium levels and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GMDTC for injection
- What this could lead to
- If it works, this could point toward a treatment to help people with high cadmium levels excrete the metal and reduce long-term health risks.
- What could go wrong
- This is a very small, early Phase IIa trial with only 11 people. It is designed mainly to check safety and how the drug works in the body, not yet to prove it is an effective treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CADMIUM EXCEEDS THE STANDARD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment
RECRUITINGGuangzhou, Guangdong, 510300, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.